Measuring the side effects of taxane therapy in oncology: The Functional Assessment of Cancer Therapy-Taxane (FACT-Taxane)

Cancer

Volumn 98, Issue 4, 2003, Pages 822-831

  Cella, David ^a,c   Peterman, Amy ^a   Hudgens, Stacie ^a   Webster, Kimberly ^a   Socinski, Mark A ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c EVANSTON NORTHWESTERN HEALTHCARE   (United States)

Author keywords

Neurotoxicity; Peripheral neuropathy; Quality of life (QOL); Taxane therapy

Indexed keywords

ANTINEOPLASTIC AGENT; TAXANE DERIVATIVE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER THERAPY; CLINICAL TRIAL; DRUG SAFETY; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL ASSESSMENT OF CANCER THERAPY; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SCORING SYSTEM; SELF REPORT; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ATTITUDE TO HEALTH; BRIDGED COMPOUNDS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; QUALITY OF LIFE; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS; TAXOIDS;

EID: 0043073211     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11578     Document Type: Article

References (24)

1. Rowinsky EK, Donehower RC. Drug therapy: Paclitaxel (Taxol). N Engl J Med. 1995;332:1004-1014.
2. Tankanow RM. Docetaxel: a taxoid for the treatment of metastatic breast cancer. Am J Health Syst Pharm. 1998;55:1777-1791.
3. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature. 1979;277:665-667.
4. Schiff PB, Horwitz SG. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A. 1980;82:1247-1259.
5. Rowinsky EK, Cazenave LA, Donehower R. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst. 1990;82:1247-1259.
6. Pronk LC, Stoter G, Verweij J. Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side effects. Cancer Treatment Rev. 1995;21:463-478.
7. Lavelle F, Bissery MC, Combeau C, et al. Preclinical evaluation of docetaxel (Taxotere). Semin Oncol. 1995;22(Suppl 4):3-16.
8. von Minckwitz G, Costa SD, Raab G, et al. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized controlled open phase IIb study. J Clin Oncol. 2001;19:3506-3515.
9. Hinton S, Catalano P, Einhorn LH, et al. Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2002;20:1859-1863.
10. Kosmidis P, Mylonakis N, Nicolaides C, et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small cell lung cancer: a phase III randomized trial. J Clin Oncol. 2002;20:3578-3585.
11. Loesch D, Robert N, Asmar L, et al. Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. J Clin Oncol. 2002;20:3857-3864.
12. Markman M, Hall J, Spitz D, et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol. 2002;20:2365-2369.
13. Choy H, Shur Y, Cmelak AJ, Mohr PJ, Johnson DH. Patterns of practice survey for non-small cell lung cancer in the U.S. Cancer. 2000;88:1336-1346.
14. Forsyth PA, Balmaceda C, Peterson K, et al. Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J Neurooncol. 1997;35:47-53.
15. Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced stage IIIB/IV non-small-cell lung cancer. J Clin Oncol. 2002;20:1335-1343.
16. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy Scale: development and validation of the general measure. J Clin Oncol. 1993;11:570-579.
17. Calhoun EA, Fishman DA, Roland PY, et al. Validity and sensitivity of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx). Proc Am Soc Clin Oncol. 2000;19:446a.
18. Cella D, Bonomi A, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer. 1995;12:199-220.
19. Cohen J. Statistical power analysis for the behavioral sciences, 2nd edition. Hillsdale, NJ: Lawrence Erlbaum Associates, Publishers, 1988.
20. Cella D, Eton DT, Fairclough DL, et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol. 2002;55:285-295.
21. Wyrwich K, Tierney W, Wolinsky F. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol. 1999;52:861-873.
22. Bennett KJ, Torrance GW. Measuring health state preferences and utilities: rating scale, time trade off and standard gamble techniques. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials, 2nd edition. Philadelphia: Lippincott-Raven, 1996:253-265.
23. Fairclough DL, Peterson H, Cella D, Bonomi P. Comparison of several model-based methods for analyzing incomplete quality of life data in cancer clinical trials. Stat Med. 1998;17:781-796.
24. Hahn EA, Webster KA, Cella D, Fairclough DL. Missing data in quality of life research in Eastern Cooperative Oncology Group (ECOG) clinical trials: problems and solutions. Stat Med. 1998;17:547-559.